
    
      Total of 56 weeks in the study period, including an up to 28-day screening period and 52-week
      treatment period, followed by 30-day post-treatment observation period.

      After the end of 52-week treatment, patients' guardians could choose to participate in a
      patient assistance program (PAP) sponsored by Sanofi and launched before first patient out
      (FPO) or reimbursement from social insurance for continued treatment.
    
  